Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 May 15;99(10):2334–2341. doi: 10.1172/JCI119414

Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery.

D Chen 1, K Krasinski 1, A Sylvester 1, J Chen 1, P D Nisen 1, V Andrés 1
PMCID: PMC508071  PMID: 9153274

Abstract

Abnormal proliferation of vascular smooth muscle cells (VSMCs) contributes to intimal hyperplasia during atherosclerosis and restenosis, but the endogenous cell cycle regulatory factors underlying VSMC growth in response to arterial injury are not well understood. In the present study, we report that downregulation of cyclin-dependent kinase 2 (cdk2) activity in serum-deprived VSMCs was associated with the formation of complexes between cdk2 and its inhibitory protein p27(KIP1) (p27). Ectopic overexpression of p27 in serum-stimulated VSMCs resulted in the inhibition of cdk2 activity and repression of cyclin A promoter activity. Collectively, these findings indicate that p27 may contribute to VSMC growth arrest in vitro. Using the rat carotid model of balloon angioplasty, a marked upregulation of p27 was observed in injured arteries. High levels of p27 expression in the media and neointima correlated with downregulation of cdk2 activity at 2 wk after angioplasty, and adenovirus-mediated overexpression of p27 in balloon-injured arteries attenuated neointimal lesion formation. Thus, the inhibition of cdk2 function and repression of cyclin A gene transcription through the induction of the endogenous p27 protein provides a mechanism for the inhibition of VSMC growth at late time points after angioplasty.

Full Text

The Full Text of this article is available as a PDF (6.0 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe J., Zhou W., Taguchi J., Takuwa N., Miki K., Okazaki H., Kurokawa K., Kumada M., Takuwa Y. Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery. Biochem Biophys Res Commun. 1994 Jan 14;198(1):16–24. doi: 10.1006/bbrc.1994.1003. [DOI] [PubMed] [Google Scholar]
  2. Andrés V., Fisher S., Wearsch P., Walsh K. Regulation of Gax homeobox gene transcription by a combination of positive factors including myocyte-specific enhancer factor 2. Mol Cell Biol. 1995 Aug;15(8):4272–4281. doi: 10.1128/mcb.15.8.4272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bennett M. R., Anglin S., McEwan J. R., Jagoe R., Newby A. C., Evan G. I. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J Clin Invest. 1994 Feb;93(2):820–828. doi: 10.1172/JCI117036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Califf R. M., Fortin D. F., Frid D. J., Harlan W. R., 3rd, Ohman E. M., Bengtson J. R., Nelson C. L., Tcheng J. E., Mark D. B., Stack R. S. Restenosis after coronary angioplasty: an overview. J Am Coll Cardiol. 1991 May;17(6 Suppl B):2B–13B. doi: 10.1016/0735-1097(91)90933-z. [DOI] [PubMed] [Google Scholar]
  5. Catzavelos C., Bhattacharya N., Ung Y. C., Wilson J. A., Roncari L., Sandhu C., Shaw P., Yeger H., Morava-Protzner I., Kapusta L. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med. 1997 Feb;3(2):227–230. doi: 10.1038/nm0297-227. [DOI] [PubMed] [Google Scholar]
  6. Chang M. W., Barr E., Lu M. M., Barton K., Leiden J. M. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 1995 Nov;96(5):2260–2268. doi: 10.1172/JCI118281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chang M. W., Barr E., Seltzer J., Jiang Y. Q., Nabel G. J., Nabel E. G., Parmacek M. S., Leiden J. M. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 1995 Jan 27;267(5197):518–522. doi: 10.1126/science.7824950. [DOI] [PubMed] [Google Scholar]
  8. Chen J., Willingham T., Shuford M., Nisen P. D. Tumor suppression and inhibition of aneuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor p27KIP1. J Clin Invest. 1996 Apr 15;97(8):1983–1988. doi: 10.1172/JCI118631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Clowes A. W., Clowes M. M. Kinetics of cellular proliferation after arterial injury. II. Inhibition of smooth muscle growth by heparin. Lab Invest. 1985 Jun;52(6):611–616. [PubMed] [Google Scholar]
  10. Clowes A. W., Reidy M. A., Clowes M. M. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest. 1983 Sep;49(3):327–333. [PubMed] [Google Scholar]
  11. Dimri G. P., Nakanishi M., Desprez P. Y., Smith J. R., Campisi J. Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein. Mol Cell Biol. 1996 Jun;16(6):2987–2997. doi: 10.1128/mcb.16.6.2987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Feldman L. J., Steg P. G., Zheng L. P., Chen D., Kearney M., McGarr S. E., Barry J. J., Dedieu J. F., Perricaudet M., Isner J. M. Low-efficiency of percutaneous adenovirus-mediated arterial gene transfer in the atherosclerotic rabbit. J Clin Invest. 1995 Jun;95(6):2662–2671. doi: 10.1172/JCI117968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Fero M. L., Rivkin M., Tasch M., Porter P., Carow C. E., Firpo E., Polyak K., Tsai L. H., Broudy V., Perlmutter R. M. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell. 1996 May 31;85(5):733–744. doi: 10.1016/s0092-8674(00)81239-8. [DOI] [PubMed] [Google Scholar]
  14. Franklin S. M., Faxon D. P. Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials. Coron Artery Dis. 1993 Mar;4(3):232–242. doi: 10.1097/00019501-199303000-00003. [DOI] [PubMed] [Google Scholar]
  15. Fuster V., Badimon L., Badimon J. J., Chesebro J. H. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med. 1992 Jan 23;326(4):242–250. doi: 10.1056/NEJM199201233260406. [DOI] [PubMed] [Google Scholar]
  16. Geary R. L., Williams J. K., Golden D., Brown D. G., Benjamin M. E., Adams M. R. Time course of cellular proliferation, intimal hyperplasia, and remodeling following angioplasty in monkeys with established atherosclerosis. A nonhuman primate model of restenosis. Arterioscler Thromb Vasc Biol. 1996 Jan;16(1):34–43. doi: 10.1161/01.atv.16.1.34. [DOI] [PubMed] [Google Scholar]
  17. Girard F., Strausfeld U., Fernandez A., Lamb N. J. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell. 1991 Dec 20;67(6):1169–1179. doi: 10.1016/0092-8674(91)90293-8. [DOI] [PubMed] [Google Scholar]
  18. Graña X., Reddy E. P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 1995 Jul 20;11(2):211–219. [PubMed] [Google Scholar]
  19. Hanke H., Strohschneider T., Oberhoff M., Betz E., Karsch K. R. Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. Circ Res. 1990 Sep;67(3):651–659. doi: 10.1161/01.res.67.3.651. [DOI] [PubMed] [Google Scholar]
  20. Harper J. W., Elledge S. J. Cdk inhibitors in development and cancer. Curr Opin Genet Dev. 1996 Feb;6(1):56–64. doi: 10.1016/s0959-437x(96)90011-8. [DOI] [PubMed] [Google Scholar]
  21. Hegele R. A. The pathogenesis of atherosclerosis. Clin Chim Acta. 1996 Mar 15;246(1-2):21–38. doi: 10.1016/0009-8981(96)06224-9. [DOI] [PubMed] [Google Scholar]
  22. Heichman K. A., Roberts J. M. Rules to replicate by. Cell. 1994 Nov 18;79(4):557–562. doi: 10.1016/0092-8674(94)90541-x. [DOI] [PubMed] [Google Scholar]
  23. Henglein B., Chenivesse X., Wang J., Eick D., Bréchot C. Structure and cell cycle-regulated transcription of the human cyclin A gene. Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5490–5494. doi: 10.1073/pnas.91.12.5490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Henthorn P., Zervos P., Raducha M., Harris H., Kadesch T. Expression of a human placental alkaline phosphatase gene in transfected cells: use as a reporter for studies of gene expression. Proc Natl Acad Sci U S A. 1988 Sep;85(17):6342–6346. doi: 10.1073/pnas.85.17.6342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Hunter T., Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell. 1994 Nov 18;79(4):573–582. doi: 10.1016/0092-8674(94)90543-6. [DOI] [PubMed] [Google Scholar]
  26. Kaltenbach M., Kober G., Scherer D., Vallbracht C. Recurrence rate after successful coronary angioplasty. Eur Heart J. 1985 Mar;6(3):276–281. doi: 10.1093/oxfordjournals.eurheartj.a061852. [DOI] [PubMed] [Google Scholar]
  27. King R. W., Jackson P. K., Kirschner M. W. Mitosis in transition. Cell. 1994 Nov 18;79(4):563–571. doi: 10.1016/0092-8674(94)90542-8. [DOI] [PubMed] [Google Scholar]
  28. Kiyokawa H., Kineman R. D., Manova-Todorova K. O., Soares V. C., Hoffman E. S., Ono M., Khanam D., Hayday A. C., Frohman L. A., Koff A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell. 1996 May 31;85(5):721–732. doi: 10.1016/s0092-8674(00)81238-6. [DOI] [PubMed] [Google Scholar]
  29. Koyama H., Raines E. W., Bornfeldt K. E., Roberts J. M., Ross R. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell. 1996 Dec 13;87(6):1069–1078. doi: 10.1016/s0092-8674(00)81801-2. [DOI] [PubMed] [Google Scholar]
  30. Leimgruber P. P., Roubin G. S., Hollman J., Cotsonis G. A., Meier B., Douglas J. S., King S. B., Jr, Gruentzig A. R. Restenosis after successful coronary angioplasty in patients with single-vessel disease. Circulation. 1986 Apr;73(4):710–717. doi: 10.1161/01.cir.73.4.710. [DOI] [PubMed] [Google Scholar]
  31. Lenfant C. NHLBI funding policies. Enhancing stability, predictability, and cost control. Circulation. 1994 Jul;90(1):1–1. doi: 10.1161/01.cir.90.1.1. [DOI] [PubMed] [Google Scholar]
  32. Libby P., Schwartz D., Brogi E., Tanaka H., Clinton S. K. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation. 1992 Dec;86(6 Suppl):III47–III52. [PubMed] [Google Scholar]
  33. Lindner V., Reidy M. A. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci U S A. 1991 May 1;88(9):3739–3743. doi: 10.1073/pnas.88.9.3739. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Liu M. W., Roubin G. S., King S. B., 3rd Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation. 1989 Jun;79(6):1374–1387. doi: 10.1161/01.cir.79.6.1374. [DOI] [PubMed] [Google Scholar]
  35. Loda M., Cukor B., Tam S. W., Lavin P., Fiorentino M., Draetta G. F., Jessup J. M., Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997 Feb;3(2):231–234. doi: 10.1038/nm0297-231. [DOI] [PubMed] [Google Scholar]
  36. Mabin T. A., Holmes D. R., Jr, Smith H. C., Vlietstra R. E., Reeder G. S., Bresnahan J. F., Bove A. A., Hammes L. N., Elveback L. R., Orszulak T. A. Follow-up clinical results in patients undergoing percutaneous transluminal coronary angioplasty. Circulation. 1985 Apr;71(4):754–760. doi: 10.1161/01.cir.71.4.754. [DOI] [PubMed] [Google Scholar]
  37. March K. L., Madison J. E., Trapnell B. C. Pharmacokinetics of adenoviral vector-mediated gene delivery to vascular smooth muscle cells: modulation by poloxamer 407 and implications for cardiovascular gene therapy. Hum Gene Ther. 1995 Jan;6(1):41–53. doi: 10.1089/hum.1995.6.1-41. [DOI] [PubMed] [Google Scholar]
  38. Morgan D. O. Principles of CDK regulation. Nature. 1995 Mar 9;374(6518):131–134. doi: 10.1038/374131a0. [DOI] [PubMed] [Google Scholar]
  39. Morishita R., Gibbons G. H., Ellison K. E., Nakajima M., Zhang L., Kaneda Y., Ogihara T., Dzau V. J. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8474–8478. doi: 10.1073/pnas.90.18.8474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Morishita R., Gibbons G. H., Ellison K. E., Nakajima M., von der Leyen H., Zhang L., Kaneda Y., Ogihara T., Dzau V. J. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest. 1994 Apr;93(4):1458–1464. doi: 10.1172/JCI117123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Morishita R., Gibbons G. H., Kaneda Y., Ogihara T., Dzau V. J. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene. 1994 Nov 4;149(1):13–19. doi: 10.1016/0378-1119(94)90406-5. [DOI] [PubMed] [Google Scholar]
  42. Motokura T., Arnold A. Cyclins and oncogenesis. Biochim Biophys Acta. 1993 May 25;1155(1):63–78. doi: 10.1016/0304-419x(93)90022-5. [DOI] [PubMed] [Google Scholar]
  43. Nabel E. G., Yang Z. Y., Plautz G., Forough R., Zhan X., Haudenschild C. C., Maciag T., Nabel G. J. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature. 1993 Apr 29;362(6423):844–846. doi: 10.1038/362844a0. [DOI] [PubMed] [Google Scholar]
  44. Nabel E. G., Yang Z., Liptay S., San H., Gordon D., Haudenschild C. C., Nabel G. J. Recombinant platelet-derived growth factor B gene expression in porcine arteries induce intimal hyperplasia in vivo. J Clin Invest. 1993 Apr;91(4):1822–1829. doi: 10.1172/JCI116394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Nakayama K., Ishida N., Shirane M., Inomata A., Inoue T., Shishido N., Horii I., Loh D. Y., Nakayama K. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 1996 May 31;85(5):707–720. doi: 10.1016/s0092-8674(00)81237-4. [DOI] [PubMed] [Google Scholar]
  46. Nobuyoshi M., Kimura T., Nosaka H., Mioka S., Ueno K., Yokoi H., Hamasaki N., Horiuchi H., Ohishi H. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol. 1988 Sep;12(3):616–623. doi: 10.1016/s0735-1097(88)80046-9. [DOI] [PubMed] [Google Scholar]
  47. Nurse P. Ordering S phase and M phase in the cell cycle. Cell. 1994 Nov 18;79(4):547–550. doi: 10.1016/0092-8674(94)90539-8. [DOI] [PubMed] [Google Scholar]
  48. Ohno T., Gordon D., San H., Pompili V. J., Imperiale M. J., Nabel G. J., Nabel E. G. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science. 1994 Aug 5;265(5173):781–784. doi: 10.1126/science.8047883. [DOI] [PubMed] [Google Scholar]
  49. Pagano M., Pepperkok R., Verde F., Ansorge W., Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J. 1992 Mar;11(3):961–971. doi: 10.1002/j.1460-2075.1992.tb05135.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Peter M., Herskowitz I. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell. 1994 Oct 21;79(2):181–184. doi: 10.1016/0092-8674(94)90186-4. [DOI] [PubMed] [Google Scholar]
  51. Pickering J. G., Weir L., Rosenfield K., Stetz J., Jekanowski J., Isner J. M. Smooth muscle cell outgrowth from human atherosclerotic plaque: implications for the assessment of lesion biology. J Am Coll Cardiol. 1992 Nov 15;20(6):1430–1439. doi: 10.1016/0735-1097(92)90259-p. [DOI] [PubMed] [Google Scholar]
  52. Polyak K., Kato J. Y., Solomon M. J., Sherr C. J., Massague J., Roberts J. M., Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 1994 Jan;8(1):9–22. doi: 10.1101/gad.8.1.9. [DOI] [PubMed] [Google Scholar]
  53. Popma J. J., Califf R. M., Topol E. J. Clinical trials of restenosis after coronary angioplasty. Circulation. 1991 Sep;84(3):1426–1436. doi: 10.1161/01.cir.84.3.1426. [DOI] [PubMed] [Google Scholar]
  54. Porter P. L., Malone K. E., Heagerty P. J., Alexander G. M., Gatti L. A., Firpo E. J., Daling J. R., Roberts J. M. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 1997 Feb;3(2):222–225. doi: 10.1038/nm0297-222. [DOI] [PubMed] [Google Scholar]
  55. Reynisdóttir I., Polyak K., Iavarone A., Massagué J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev. 1995 Aug 1;9(15):1831–1845. doi: 10.1101/gad.9.15.1831. [DOI] [PubMed] [Google Scholar]
  56. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993 Apr 29;362(6423):801–809. doi: 10.1038/362801a0. [DOI] [PubMed] [Google Scholar]
  57. Rothman A., Kulik T. J., Taubman M. B., Berk B. C., Smith C. W., Nadal-Ginard B. Development and characterization of a cloned rat pulmonary arterial smooth muscle cell line that maintains differentiated properties through multiple subcultures. Circulation. 1992 Dec;86(6):1977–1986. doi: 10.1161/01.cir.86.6.1977. [DOI] [PubMed] [Google Scholar]
  58. Schulze A., Zerfass-Thome K., Bergès J., Middendorp S., Jansen-Dürr P., Henglein B. Anchorage-dependent transcription of the cyclin A gene. Mol Cell Biol. 1996 Sep;16(9):4632–4638. doi: 10.1128/mcb.16.9.4632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Schulze A., Zerfass K., Spitkovsky D., Middendorp S., Bergès J., Helin K., Jansen-Dürr P., Henglein B. Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site. Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11264–11268. doi: 10.1073/pnas.92.24.11264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995 May 15;9(10):1149–1163. doi: 10.1101/gad.9.10.1149. [DOI] [PubMed] [Google Scholar]
  61. Shi Y., Fard A., Galeo A., Hutchinson H. G., Vermani P., Dodge G. R., Hall D. J., Shaheen F., Zalewski A. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation. 1994 Aug;90(2):944–951. doi: 10.1161/01.cir.90.2.944. [DOI] [PubMed] [Google Scholar]
  62. Simons M., Edelman E. R., DeKeyser J. L., Langer R., Rosenberg R. D. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature. 1992 Sep 3;359(6390):67–70. doi: 10.1038/359067a0. [DOI] [PubMed] [Google Scholar]
  63. Speir E., Modali R., Huang E. S., Leon M. B., Shawl F., Finkel T., Epstein S. E. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 1994 Jul 15;265(5170):391–394. doi: 10.1126/science.8023160. [DOI] [PubMed] [Google Scholar]
  64. Wei G. L., Krasinski K., Kearney M., Isner J. M., Walsh K., Andrés V. Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Circ Res. 1997 Mar;80(3):418–426. [PubMed] [Google Scholar]
  65. Weinberg R. A. The retinoblastoma protein and cell cycle control. Cell. 1995 May 5;81(3):323–330. doi: 10.1016/0092-8674(95)90385-2. [DOI] [PubMed] [Google Scholar]
  66. Wijns W., Serruys P. W., Reiber J. H., de Feyter P. J., van den Brand M., Simoons M. L., Hugenholtz P. G. Early detection of restenosis after successful percutaneous transluminal coronary angioplasty by exercise-redistribution thallium scintigraphy. Am J Cardiol. 1985 Feb 1;55(4):357–361. doi: 10.1016/0002-9149(85)90375-3. [DOI] [PubMed] [Google Scholar]
  67. Yang Z. Y., Simari R. D., Perkins N. D., San H., Gordon D., Nabel G. J., Nabel E. G. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7905–7910. doi: 10.1073/pnas.93.15.7905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Zerfass-Thome K., Schulze A., Zwerschke W., Vogt B., Helin K., Bartek J., Henglein B., Jansen-Dürr P. p27KIP1 blocks cyclin E-dependent transactivation of cyclin A gene expression. Mol Cell Biol. 1997 Jan;17(1):407–415. doi: 10.1128/mcb.17.1.407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. van den Heuvel S., Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science. 1993 Dec 24;262(5142):2050–2054. doi: 10.1126/science.8266103. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES